NCT00382824

Effects of Coenzyme Q10 in Progressive Supranuclear Palsy (PSP)

Effects of Coenzyme Q10 in Progressive Supranuclear Palsy (PSP): A Multicenter, Randomized, Placebo-controlled, Double Blind Study

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 61 (actual)
• Sponsor: Lahey Clinic · Academic / Other
• Sex: All
• Age: 30 Years
• Healthy volunteers: Not accepted

Summary

The clinical syndrome of PSP responds poorly to all available forms of therapy used in Parkinson's Disease (PD). Currently, no effective treatment exists. Coenzyme Q10 in high doses has been shown to be a beneficial therapy in PD and might possibly be a beneficial therapy for PSP. This study will compare the efficacy, safety and tolerability of Coenzyme Q10 versus placebo in patients with atypical parkinsonian syndrome, progressive supranuclear palsy (PSP).

Detailed description

The study is designed as a multicenter randomized, placebo-controlled, double blind trial. Up to 60 patients with PSP will be enrolled at several centers in the United States

Conditions

• Progressive Supranuclear Palsy

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Coenzyme Q10	active drug
OTHER	Placebo	Placebo

Timeline

• Start date: 2006-09-01
• Primary completion: 2013-09-01
• Completion: 2015-01-01
• First posted: 2006-10-02
• Last updated: 2019-08-01
• Results posted: 2019-08-01

Locations

3 sites across 1 country: United States